Eledon Pharmaceuticals

Yahoo Finance • 15 days ago

Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon repo... Full story

Yahoo Finance • 2 months ago

Eledon Pharmaceuticals GAAP EPS of -$0.52 beats by $0.15

* Eledon Pharmaceuticals press release [https://seekingalpha.com/pr/20445666-eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-operating-and-financial] (ELDN [https://seekingalpha.com/symbol/ELDN]): FY GAAP EPS of -$0.52 b... Full story

Yahoo Finance • 2 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continu... Full story

Yahoo Finance • 6 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplan... Full story

Yahoo Finance • 6 months ago

Eledon Pharmaceuticals GAAP EPS of -$0.21

* Eledon Pharmaceuticals press release [https://seekingalpha.com/pr/20308730-eledon-pharmaceuticals-announces-recent-business-highlights-and-third-quarter-2025-financial] (ELDN [https://seekingalpha.com/symbol/ELDN]): Q3 GAAP EPS of -$0.... Full story

Yahoo Finance • 6 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Data supports advancement into Ph... Full story

Yahoo Finance • 6 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering p... Full story

Yahoo Finance • 6 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a favorable safety and toler... Full story

Yahoo Finance • 7 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

IRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the American Society of Nephrology’s upcoming Kidney Week 2025 Annual Meeti... Full story

Yahoo Finance • 7 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upco... Full story

Yahoo Finance • 8 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Can... Full story

Yahoo Finance • 9 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in k... Full story

Yahoo Finance • 9 months ago

Stay updated with the stocks that are on the move in today's after-hours session.

The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. [postmarket] AFTER HOURS GAINERS TICKER CHA... Full story

Yahoo Finance • 9 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports th... Full story

Yahoo Finance • 10 months ago

Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of r... Full story

Yahoo Finance • 10 months ago

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: EL... Full story

Yahoo Finance • 10 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET. The event will fe... Full story

Yahoo Finance • last year

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subje... Full story

Yahoo Finance • last year

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcomi... Full story

Yahoo Finance • last year

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L) with potential to im... Full story